Amgen Regeneron Pharmaceuticals Stock Update
Amgen Inc. is not an unknown name in the financial world. The company stock is valued at $234 today. AMGN met some serious volatility in the last year. However, its stock stands on firm ground today. Starting at $233 a year ago, AMGN is worth $234 today, showing that the company has ‘really kept up’.
In price movements, Amgen Regeneron Pharmaceuticals boasts a day’s range of $241.98 – $245.50, a 52-week range of $210-$277 and a share volume of 2M. The company also holds a market cap of 146 billion, a beta value of 0.71 and a PE ratio of 21.
GlaxoSmithKline Stands With Amgen In Patent Fight!
Amgen is headquartered in America. With the ticker ‘NASDAQ: AMGN‘, AMGN is a biotechnology stock. The company was established in 1988. It initially focused on neurotrophic factors and is now going in ‘regenerative capabilities.
Amgen’s 1st quarter results posted on April 27 were also not that impressive.
GlaxoSmithKline has backed Amgen in a recent patent fight. Glaxo is a big name in the pharmaceutical industry. They believe that patent disputes have distraught their R&D efforts. (Read: How to stop eating betel- Areca Nut).
A Look At Amgen Ahead!
Amgen is a leading biotech company. Its values are based on science and innovation. It is constantly on the lookout for new ideas and discoveries for patients who have serious ailments.
Moreover, with Covid-19 still looming in 2021 and ahead, and Amgen being a biotechnology company, there could be a lot coming up for the company. It is already making new drugs for ailments and it now really needs to revolutionize the way it is operating to compete in such high and competitive times.
Stay tuned for more updates at Tech Unveiled.
92 total views, 1 views today